Abstract 1868P
Background
Patients with incurable cancer often face difficult decisions about their care. Shared decision making (SDM) can help people make the decisions that are right for them, by supporting understanding and ensuring their priorities are considered. Essential for this is health literacy (HL) - the personal competencies and situational resources needed for people to process information to make decisions. This study sought to understand the barriers to SDM in the context of HL from the perspective of patients and clinicians, and consider how they may be overcome.
Methods
This mixed methods study comprised: 1) semi-structured interviews with patients with incurable cancer and suspected HL difficulties, identified by clinicians from 2 district hospitals; and 2) an online survey of NHS healthcare professionals caring for patients with incurable cancer. Interview data were analysed using the Framework Approach to identify important and recurrent themes. For the survey, a descriptive analysis was carried out for the quantitative data, and thematic analysis for the qualitative data.
Results
Twenty-one interviews were conducted. Patients had a range of diagnoses and had received various treatments. Themes related to experiences (supportive staff in an imperfect system, additional pressure from COVID-19, in the expert’s hands, treatment not so bad) and barriers to SDM (emotional hurdles, accessing and understanding information, wanting to be a good patient). Survey participants (N=70) included doctors, nurses, and a pharmacist. Views towards SDM ranged from those who aim to ‘always’ use it, to those who feel its use should be limited. Patient, clinician, and situational barriers were identified. Key challenges for SDM include the persistence of paternalistic clinician-patient roles, dealing with emotional hurdles, and practical issues.
Conclusions
There are socio-cultural, emotional and system barriers to SDM in incurable cancer for those with HL difficulties. Addressing this combination of issues will be important to fully embed its use in practice. Recommendations to improve SDM range from large scale policy changes to provision of easily accessible and understandable patient information and decision aids in a variety of formats.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Southampton.
Funding
Robert White Legacy Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05